Sign In
Buy OCGN
$1.22
+0.0100 (+0.83%)
At Close: Jun 15, 2026
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
06:08am, Wednesday, 15'th May 2024
LOS ANGELES , May 15, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Co
Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
01:39pm, Tuesday, 14'th May 2024
Ocugen, Inc. (NASDAQ:OCGN ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, CEO & Co-Founde
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
10:00am, Tuesday, 14'th May 2024
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ:OCGN) for for violations of 10(
Ocugen Provides Business Update with First Quarter 2024 Financial Results
08:00am, Tuesday, 14'th May 2024
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progress OCU400 on track to meet 2026 Biologics License Application (BLA) and Market Au
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
01:00pm, Monday, 13'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com
New York , May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, b
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
04:05pm, Friday, 10'th May 2024
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell
LOS ANGELES, CA / ACCESSWIRE / May 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Com
Ocugen to Present at May 2024 Investor Conferences
07:45am, Friday, 10'th May 2024
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel ge
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses In Excess of $250,000 to Contact the Firm
08:00am, Thursday, 09'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Comp
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
03:30pm, Wednesday, 08'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Comp
Millionaire Blueprint: 3 Stocks Under $5 With Massive Growth Potential by 2028
06:00am, Wednesday, 08'th May 2024
Opportunities can lurk in plain sight in the ever-changing stock market landscape, waiting for experienced investors to recognize their potential. Three stocks stand out among the many investing possi
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
02:00pm, Tuesday, 07'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Comp
Ocugen stock is a good speculative buy but there's 1 key risk
09:51am, Tuesday, 07'th May 2024
Ocugen (NASDAQ: OCGN) stock price has launched higher since last year, helped by the rising hopes that OCU400 will be approved by the Food and Drug Administration (FDA). The stock surged by over 378%
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
08:00am, Monday, 06'th May 2024
LOS ANGELES, CA / ACCESSWIRE / May 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Comp
